Subtraction hybridization combined with induction of
cancer cell terminal differentiation in human
melanoma cells identified
melanoma differentiation-associated gene-7/
interleukin-24 (mda-7/IL-24) and SARI (suppressor of AP-1, induced by IFN) that display potent antitumor activity. These genes are not constitutively expressed in
cancer cells and forced expression of mda-7/IL-24 (Ad.mda-7) or SARI (Ad.SARI) promotes
cancer-specific cell death. Ectopic expression of mda-7/IL-24 induces SARI
mRNA and
protein in a panel of different
cancer cells, leading to cell death, without harming corresponding normal cells. Simultaneous inhibition of K-ras downstream
extracellular signal-regulated kinase 1/2 signaling in
pancreatic cancer cells reverses the translational block of MDA-7/IL-24 and induces SARI expression and cell death. Using SARI-antisense-based approaches, we demonstrate that SARI expression is necessary for mda-7/IL-24 antitumor effects. Secreted MDA-7/IL-24
protein induces antitumor "bystander" effects by promoting its own expression. Recombinant MDA-7/IL-24 (His-MDA-7) induces SARI expression, supporting the involvement of SARI in the MDA-7/IL-24-driven autocrine loop, culminating in antitumor effects. Moreover, His-MDA-7, after binding to its cognate receptors (IL-20R1/IL-20R2 or IL-22R/IL-20R2), induces intracellular signaling by phosphorylation of
p38 MAPK, leading to transcription of a family of growth arrest and DNA damage inducible (GADD) genes, culminating in apoptosis. Inhibition of
p38 MAPK fails to induce SARI following Ad.mda-7
infection. These findings reveal the significance of the mda-7/IL-24-SARI axis in
cancer-specific killing and provide a potential strategy for treating both local and metastatic disease.